selegiline also known ldeprenyl sold brand names eldepryl emsam selgin among names medication used treatment parkinsons disease major depressive provided form capsule tablet taken mouth orally disintegrating tablets taken tongue parkinsons disease patch applied skin depression selegiline acts monoamine oxidase inhibitor increases levels monoamine neurotransmitters brain typical clinical doses used parkinsons disease selegiline selective irreversible inhibitor monoamine oxidase b maob increasing levels dopamine brain larger doses mgday loses specificity maob also inhibits maoa increases serotonin norepinephrine levels brain pill form selegiline used treat symptoms parkinsons often used adjunct drugs levodopa ldopa although used offlabel rationale adding selegiline levodopa decrease required dose levodopa thus reduce motor complications levodopa selegiline delays point levodopa treatment becomes necessary months months evidence selegiline acts neuroprotectant reduces rate disease progression though selegiline also used offlabel palliative treatment dementia alzheimers selegiline also delivered via transdermal patch used treatment major depressive administration transdermal selegiline bypasses hepatic first pass metabolism avoids inhibition gastrointestinal hepatic maoa activity would result increase foodborne tyramine blood possible related adverse effects allowing sufficient amount selegiline reach brain antidepressant quantitative review published found pooled results pivotal trials number needed treat sign effect size low number better patch symptom reduction remission number needed harm inverse nnt high number better ranged sexual side effects application site regard likelihood helped harmed lhh analysis showed selegiline patch times likely lead remission vs discontinuation due side effects lhh remission vs incidence insomnia lhh remission vs discontinuation due insomnia lhh remission vs insomnia sexual dysfunction human uses forms selegiline pregnancy category c studies pregnant lab animals shown adverse effects fetus adequate studies side effects tablet form conjunction levodopa include decreasing order frequency nausea hallucinations confusion depression loss balance insomnia increased involuntary movements agitation slow irregular heart rate delusions hypertension new increased angina pectoris side effects due high dopamine signaling alleviated reducing dose main side effects patch form depression include applicationsite reactions insomnia diarrhea sore selegiline patch carries black box warning possible increased risk suicide especially young antidepressants since oral patch forms come strong warnings combining selegiline drugs could produce serotonin syndrome ssris cough medicine selegiline combination opioid analgesic pethidine recommended lead severe adverse several synthetic opioids tramadol methadone well various triptans contraindicated due potential serotonin birth control pills containing ethinylestradiol progestin increase bioavailability selegiline high levels lead loss maob selectivity selegiline may begin inhibiting maoa well increases susceptibility side effects nonselective maois tyramineinduced hypertensive crisis serotonin toxicity combined serotonergic forms drug carry warnings food restrictions avoid hypertensive crisis associated mao patch form created part overcome food restrictions clinical trials showed successful additionally postmarketing surveillance april october selfreports possible hypertensive events hypertension made exposures drug none accompanied objective clinical lowest dose patch method delivery hours require dietary higher doses patch oral formulations whether combination older nonselective maois combination reversible maoa inhibitor moclobemide require lowtyramine selegiline selective inhibitor maob irreversibly inhibiting binding generally believed exert effects blocking breakdown dopamine thus increasing however recent evidence suggests maoa solely almost entirely responsible metabolism possible neuroprotective properties may due protecting nearby neurons free oxygen radicals released maob activity higher doses selegiline loses selectivity maob inhibits maoa selegiline potentiates release catecholamines independent maob inhibiting action called first synthetic catecholaminergic activity enhancer selegiline also inhibits increase effects nicotine selegiline also appears activate receptors relatively high affinity receptors approximately selegiline oral bioavailability increases ingested together fatty meal molecule fat selegiline metabolites bind extensively plasma proteins rate cross barrier enter brain concentrated thalamus basal ganglia midbrain cingulate selegiline mostly metabolized intestines liver metabolites excreted buccal administration selegiline results higher bioavailability reproducible blood concentration produces fewer amphetamine metabolites oral tablet selegiline metabolized cytochrome ldesmethylselegiline desmethylselegiline activity maob much less thought metabolized levomethamphetamine less potent two enantiomers methamphetamine converted levoamphetamine less potent two enantiomers amphetamine regards psychological effects due presence metabolites people taking selegiline may test positive amphetamine methamphetamine drug screening amphetamine metabolites may contribute selegilines ability inhibit reuptake neurotransmitters dopamine norepinephrine also associated orthostatic hypotension recovery selegiline urine high caused researchers question clinical relevance amphetamine amphetamine metabolites hydroxylated phase ii conjugated glucuronyltransferase newer antiparkinson maob inhibitor rasagiline metabolizes amphetaminelike following application patch humans average selegiline content delivered systemically hours transdermal dosing results significantly higher exposure selegiline lower exposure metabolites compared oral dosing due extensive firstpass metabolism pill form low firstpass metabolism patch form site application significant factor drug distributed humans selegiline accumulate skin metabolized selegiline belongs phenethylamine amphetamine chemical families also known ldeprenyl well compound derivative levomethamphetamine lmethamphetamine propargyl group attached nitrogen atom detail borrowed pargyline older maob inhibitor phenylalkylamine selegiline levorotatory enantiomer racemic mixture deprenyl selegiline synthesized alkylation using propargyl another clinically used maoi amphetamine class tranylcypromine following discovery tuberculosis drug iproniazid elevated mood people taking subsequent discovery effect likely due inhibition mao many people companies started trying discover mao inhibitors use antidepressants selegiline discovered zoltan ecseri hungarian drug company chinoin part sanofi since called chinoin received patent drug compound first published scientific literature english work biology effects animals humans conducted group led j√≥zsef knoll semmelweis university also deprenyl racemic compound mixture two isomers called enantiomers work determined levorotatory enantiomer potent maoinhibitor published subsequent work done single enantiomer knoll showed selegiline selectively inhibits bisoform monoamine oxidase maob proposed unlikely cause infamous cheese effect hypertensive crisis resulting consuming foods containing tyramine occurs nonselective mao inhibitors years later two parkinsons disease researchers based vienna peter riederer walther birkmayer realized selegiline could useful parkinsons disease one colleagues prof moussa bh youdim visited knoll budapest took selegiline vienna birkmayers group published first paper effect selegiline parkinsons speculation could useful antiaging drug somerset pharmaceuticals new jersey acquired us rights develop selegiline filed new drug application nda fda market drug parkinsons disease nda review somerset acquired joint venture two generic drug companies mylan bolan selegiline approved parkinsons disease fda j alexander bodkin mclean hospital affiliate harvard medical school began collaboration somerset develop delivery selegiline via transdermal patch order avoid well known dietary restrictions mao somerset obtained fda approval market patch joseph knoll team credited developed selegiline although selegelines development potential treatment parkinsons alzheimers major depressive disorder headed teams knoll remained forefront research potential longevity enhancing effects selegiline death knoll published selegiline deprenyl slows brain aging wherein claims humans maintenance sexual maturity deprenyl daily time promising prophylactic treatment fight age related decay behavioral performances prolonging life preventing delaying onset agerelated neurodegenerative diseases parkinsons mechanism selegilines longevitypromoting effect researched several groups including joseph knoll associates semmelweis university drug determined catecholaminergic activity enhancer present minuscule concentrations far monoamine oxidase inhibitory activity observed thereby potentiating release catecholamine neurotransmitters response stimuli knoll maintains microdoses selegiline act synthetic analogue known unknown trace amine order preserve brain catecholaminergic system perceives integral organisms ability function adaptive goaldirected motivated manner advancing physical age enhancer regulation catecholaminergic brain stem neurons plays key role controlling uphill period life transition adolescence adulthood results longevity studies support hypothesis quality duration life rests upon inborn efficiency catcholaminergic brain machinery ie high performing longliving individual active slowly deteriorating catecholaminergic system low performing shorter living peer thus better brain engine allows better performance longer lifespan since catecholaminergic serotonergic neurons brain stem key importance ensuring mammalian organism works purposeful motivated goaldirected entity hard overestimate significance finding safe efficient means slow decay systems passing time conclusion maintenance deprenyl keeps catecholaminergic neurnsn higher activity level safe efficient anti aging therapy follows discovery enhancer regulation catecholaminergic neurons brain stem finding regulation starts working high activity level weaning enhanced activity subsists uphill period life sexual hormones dampen enhancer regulation catecholaminergic serotonergic neurons brain stem event signifies transition developmental longevity postdevelopmental longevity downhill period selegiline considered clinical subclinical dosages used offlabel improve cognitive performance shown protective activity range neurotoxins increase production several brain growth factors nerve growth factor brainderived neurotrophic factor glial cellderived neurotrophic demonstrated numerous animal models improve learning ability preserve ischemia e ecstasy book examining uses street drug ecstasy uk writer activist ecstasy advocate nicholas saunders highlighted test results showing certain consignments drug also contained consignments ecstasy known strawberry contained saunders described potentially dangerous combination ketamine ephedrine selegiline consignment sitting duck ecstasy david pearce wrote hedonistic six weeks starting taking gregg hurwitzs novel selegiline emsam tyraminecontaining food used assassinate president united states veterinary medicine selegiline sold brand name anipryl manufactured zoetis used dogs treat canine cognitive dysfunction higher doses pituitarydependent hyperadrenocorticism canine cognitive dysfunction form dementia mimics alzheimers disease humans geriatric dogs treated selegiline show improvements sleeping pattern reduced incontinence increased activity level show improvements one though labeled dog use selegiline used offlabel geriatric cats cognitive selegilines efficacy treating pituitarydependent hyperadrenocorticism theoretically works increasing dopamine levels downregulates release acth eventually leading reduced levels claim selegiline effective treating pdh caused lesions anterior pituitary comprise canine greatest sign improvement lessening abdominal side effects dogs uncommon include vomiting diarrhea diminished hearing salivation decreased weight behavioral changes hyperactivity listlessness disorientation repetitive selegiline appear clinical effect selegiline limitedly studied treatment attention deficit hyperactivity disorder adhd childrenadolescents small randomized trial selegiline treatment adhd children improvements attention hyperactivity learningmemory performance small clinical randomized trial compared selegiline methylphenidate first line treatment adhd reported equivalent efficacy assessed parent teacher another small randomized controlled trial selegiline treatment adult adhd high dose medication weeks significantly effective placebo improving stimulants phenylethanolamine httpsenwikipediaorgwikiselegiline